查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1974003

治療性疫苗市場分析及預測（至2035年）：類型、產品類型、技術、應用、最終用戶、組成部分、製程、部署模式、解決方案

Therapeutic Vaccines Market Analysis and Forecast to 2035: Type, Product, Technology, Application, End User, Component, Process, Deployment, Solutions
出版日期: | 出版商: Global Insight Services | 英文 489 Pages | 商品交期: 3-5個工作天內

價格
簡介目錄

預計治療性疫苗市場規模將從2024年的638億美元成長到2034年的1,768億美元，複合年成長率約為10.7%。治療性疫苗市場涵蓋旨在透過刺激免疫系統增強其反應來治療現有疾病的疫苗。與預防性疫苗不同，這些疫苗針對的是慢性感染疾病、癌症和自體免疫疾病。生物技術的進步和慢性病發病率的上升正在推動市場成長。關鍵發展包括個人化疫苗和新型遞送系統，這些技術能夠滿足尚未滿足的醫療需求，並展現出良好的治療前景。

治療性疫苗市場正經歷強勁成長，這主要得益於免疫療法的進步和慢性病盛行率的上升。癌症疫苗領域表現突出，這得益於針對腫瘤抗原的創新療法。預防性疫苗，特別是針對人類乳突病毒 (HPV) 和肝炎的疫苗，由於公眾意識的提高和預防策略的完善，發展勢頭強勁。感染疾病疫苗也緊跟著，針對愛滋病和結核病的新方法層出不窮。個人化疫苗正成為一個充滿前景的領域，它能夠根據個人的基因譜提供客製化的解決方案。佐劑技術正在提高疫苗的效力，並促進市場擴張。 mRNA疫苗的興起及其近期取得的成功，預示著其快速研發和推廣的潛力。自體免疫疾病疫苗細分市場也受益於疾病研究的進展，例如類風濕性關節炎。製藥公司之間的策略聯盟和合作正在促進創新並加速臨床試驗。監管政策的製定和支持進一步推動了市場動態，為未來的發展機會鋪平了道路。

市場區隔
種類 癌症疫苗、感染疾病疫苗、自體免疫疾病疫苗、神經系統疾病疫苗
產品 預防性和治療性疫苗
科技 重組技術、結合疫苗、減毒活病毒疫苗、去去活化疫苗、合成疫苗
適用的 腫瘤學、感染疾病、自體免疫疾病、神經系統疾病
最終用戶 醫院、診所、研究機構、製藥公司
成分 抗原、佐劑
流程 臨床前試驗、臨床試驗及生產製造
實施表格 本機部署、雲端部署
解決方案 疫苗研發、疫苗生產、疫苗分發

市場概況：

治療性疫苗市場正經歷動態的市場格局，其特徵是市場佔有率波動、競爭激烈的定價策略以及新產品的湧現。市場成長主要得益於對個人化醫療日益成長的需求以及疫苗技術的突破性創新。主要產業參與者正策略性地推出先進的治療性疫苗，以滿足多樣化的醫療需求並擴大市場佔有率。治療性疫苗市場的競爭異常激烈，主要企業競相透過創新和策略聯盟來爭取主導。監管影響至關重要，嚴格的核准流程和合規標準會影響市場准入和擴張。北美和歐洲憑藉其強大的醫療保健基礎設施和支持性的法規結構，處於市場領先地位。亞太地區正崛起為一個盈利的市場，這得益於醫療保健投資的增加和公眾意識的提高。隨著產業的不斷發展，能夠駕馭監管環境並充分利用技術進步的相關人員將擁有眾多機會。

主要趨勢和促進因素：

受生物技術和個人化醫療進步的推動，治療性疫苗市場正經歷強勁成長。關鍵趨勢包括針對癌症和自體免疫疾病等慢性疾病的疫苗研發。這些創新正將重點從傳統的預防性疫苗轉向治療性應用，從而開闢新的治療途徑。 mRNA和病毒載體平台等尖端技術的整合正在加速開發更有效的疫苗。慢性疾病的日益增多和對標靶治療需求的成長是推動該市場發展的關鍵因素。製藥公司正在加大研發投入，以開發提供個人化治療方案的疫苗。監管核准的增加以及生物技術公司與學術機構之間合作的加強也支持了這一趨勢。在醫療基礎設施正在發展的新興市場，治療性疫苗正獲得認可，並展現出許多機會。能夠成功應對監管環境並證明臨床療效的公司將佔據有利地位。此外，免疫療法的進步和聯合治療的日益普及預計將進一步推動市場成長。隨著對個人化醫療的日益關注，治療性疫苗市場預計將顯著擴張。

限制與挑戰：

治療性疫苗市場面臨許多顯著的限制和挑戰。其中一個關鍵挑戰是疫苗研發高成本，需要對研發和臨床試驗進行大量投資。這種經濟負擔可能會阻礙中小企業的發展，並限制創新。監管障礙也構成重大阻礙，複雜的核准流程可能會延遲疫苗上市並增加成本。其他市場挑戰包括公眾認知和疫苗猶豫，這些因素會阻礙疫苗的接受度和廣泛應用。物流配送的挑戰，尤其是在資源匱乏的地區，進一步加劇了市場擴張的難度。確保低溫運輸完整性和覆蓋偏遠地區始終是需要克服的難題。最後，疾病流行程度的區域差異需要客製化疫苗解決方案，這使得標準化和擴充性變得更加複雜。所有這些因素共同構成了治療性疫苗成長和廣泛應用的重大挑戰。

目錄

第1章執行摘要

第2章 市場亮點

第3章 市場動態

  • 宏觀經濟分析
  • 市場趨勢
  • 市場促進因素
  • 市場機遇
  • 市場限制
  • 複合年均成長率：成長分析
  • 影響分析
  • 新興市場
  • 技術藍圖
  • 戰略框架

第4章 細分市場分析

  • 市場規模及預測：依類型
    • 癌症疫苗
    • 感染疾病疫苗
    • 自體免疫疾病疫苗
    • 神經系統疾病疫苗
  • 市場規模及預測：依產品分類
    • 預防性疫苗
    • 治療性疫苗
  • 市場規模及預測：依技術分類
    • 重組技術
    • 結合疫苗
    • 活病毒疫苗
    • 去活化疫苗
    • 合成疫苗
  • 市場規模及預測：依應用領域分類
    • 腫瘤學
    • 感染疾病
    • 自體免疫疾病
    • 神經系統疾病
  • 市場規模及預測：依最終用戶分類
    • 醫院
    • 診所
    • 研究所
    • 製藥公司
  • 市場規模及預測：依組件分類
    • 抗原
    • 佐劑
  • 市場規模及預測：依製程分類
    • 臨床前試驗
    • 臨床試驗
    • 製造業
  • 市場規模及預測：依發展狀況
    • 本地部署
    • 基於雲端的
  • 市場規模及預測：按解決方案分類
    • 疫苗研發
    • 疫苗生產
    • 疫苗分發

第5章 區域分析

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 拉丁美洲
    • 巴西
    • 阿根廷
    • 其他拉丁美洲地區
  • 亞太地區
    • 中國
    • 印度
    • 韓國
    • 日本
    • 澳洲
    • 台灣
    • 亞太其他地區
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 西班牙
    • 義大利
    • 其他歐洲地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非
    • 撒哈拉以南非洲
    • 其他中東和非洲地區

第6章 市場策略

  • 需求與供給差距分析
  • 貿易和物流限制
  • 價格、成本和利潤率趨勢
  • 市場滲透率
  • 消費者分析
  • 法規概述

第7章 競爭訊息

  • 市場定位
  • 市場占有率
  • 競爭基準
  • 主要企業的策略

第8章 公司簡介

  • Inovio Pharmaceuticals
  • Bavarian Nordic
  • Hookipa Pharma
  • GlobeImmune
  • ImmunoVaccine Technologies
  • Valneva
  • OncoTherapy Science
  • Vaxil BioTherapeutics
  • CEL-SCI Corporation
  • Transgene
  • Agenus
  • Scancell Holdings
  • Oncolytics Biotech
  • Genocea Biosciences
  • Heat Biologics
  • BioNTech
  • Altimmune
  • VBI Vaccines
  • Imugene
  • Vaccibody

第9章：關於我們

簡介目錄
Product Code: GIS33227

Therapeutic Vaccines Market is anticipated to expand from $63.8 billion in 2024 to $176.8 billion by 2034, growing at a CAGR of approximately 10.7%. The Therapeutic Vaccines Market encompasses vaccines designed to treat existing diseases by stimulating the immune system to enhance its response. Unlike preventive vaccines, these target chronic infections, cancer, and autoimmune disorders. Advances in biotechnology and increasing prevalence of chronic diseases propel market growth. Key developments include personalized vaccines and novel delivery systems, addressing unmet medical needs and offering promising therapeutic prospects.

The Therapeutic Vaccines Market is experiencing robust growth, propelled by advances in immunotherapy and increasing prevalence of chronic diseases. The cancer vaccines segment leads in performance, driven by innovative treatments targeting tumor antigens. Prophylactic vaccines, particularly for HPV and hepatitis, are gaining momentum due to heightened awareness and prevention strategies. Infectious disease vaccines follow closely, with a focus on novel approaches for HIV and tuberculosis. Personalized vaccines are emerging as a promising area, offering tailored solutions based on individual genetic profiles. Adjuvant technologies are enhancing vaccine efficacy, contributing to market expansion. The rise of mRNA-based vaccines, exemplified by recent successes, underscores the potential for rapid development and deployment. The autoimmune disease vaccines sub-segment is also witnessing growth, as research into diseases like rheumatoid arthritis progresses. Strategic partnerships and collaborations among pharmaceutical companies are fostering innovation and accelerating clinical trials. Regulatory advancements and supportive policies further bolster market dynamics, paving the way for future opportunities.

Market Segmentation
TypeCancer Vaccines, Infectious Disease Vaccines, Autoimmune Disease Vaccines, Neurological Disorder Vaccines
ProductProphylactic Vaccines, Therapeutic Vaccines
TechnologyRecombinant Technology, Conjugate Vaccines, Live Attenuated Vaccines, Inactivated Vaccines, Synthetic Vaccines
ApplicationOncology, Infectious Diseases, Autoimmune Disorders, Neurological Disorders
End UserHospitals, Clinics, Research Institutes, Pharmaceutical Companies
ComponentAntigens, Adjuvants
ProcessPreclinical Testing, Clinical Trials, Manufacturing
DeploymentOn-premise, Cloud-based
SolutionsVaccine Development, Vaccine Manufacturing, Vaccine Distribution

Market Snapshot:

Therapeutic vaccines are experiencing a dynamic market landscape, characterized by evolving market share, competitive pricing strategies, and a surge in new product launches. The market's growth is propelled by increasing demand for personalized medicine and breakthrough innovations in vaccine technology. Key industry players are strategically introducing advanced therapeutic vaccines to cater to diverse medical needs, enhancing their market presence. Competition in the therapeutic vaccines market is intense, with major companies vying for dominance through innovation and strategic alliances. Regulatory influences play a vital role, as stringent approval processes and compliance standards impact market entry and expansion. North America and Europe are at the forefront, driven by robust healthcare infrastructure and supportive regulatory frameworks. The Asia-Pacific region is emerging as a lucrative market, fueled by rising healthcare investments and increasing awareness. As the industry evolves, opportunities abound for stakeholders who can navigate regulatory landscapes and leverage technological advancements.

Geographical Overview:

The therapeutic vaccines market is witnessing robust growth across various regions, each presenting unique opportunities. North America leads the charge, driven by substantial investments in biotechnology and a strong focus on research and development. The region's well-established healthcare infrastructure and supportive regulatory environment further bolster market expansion. Europe follows closely, with significant advancements in immunotherapy and a growing emphasis on personalized medicine. The region's commitment to innovation and collaboration among key stakeholders enhances its market position. In the Asia Pacific, the market is expanding rapidly, propelled by increasing healthcare expenditure and rising awareness of therapeutic vaccines. Countries like China and India are emerging as key players, with government initiatives supporting biotechnology advancements. Latin America and the Middle East & Africa are burgeoning markets with untapped potential. In Latin America, improved healthcare access and rising demand for advanced treatments drive growth. Meanwhile, the Middle East & Africa are recognizing the benefits of therapeutic vaccines in addressing regional health challenges.

Key Trends and Drivers:

The therapeutic vaccines market is experiencing robust growth, driven by advancements in biotechnology and personalized medicine. Key trends include the development of vaccines targeting chronic diseases such as cancer and autoimmune disorders. These innovations are shifting the focus from traditional prophylactic vaccines to therapeutic applications, offering new avenues for treatment. The integration of cutting-edge technologies like mRNA and viral vector platforms is accelerating the development of more effective vaccines. The rising prevalence of chronic diseases and the growing demand for targeted therapies are significant drivers for this market. Pharmaceutical companies are increasingly investing in research and development to create vaccines that offer personalized treatment options. This trend is supported by increasing regulatory approvals and collaborations between biotech firms and academic institutions. Opportunities abound in emerging markets where healthcare infrastructure is improving, and there is a growing awareness of therapeutic vaccines. Companies that can navigate regulatory landscapes and demonstrate clinical efficacy are well-positioned for success. Additionally, advancements in immunotherapy and the increasing acceptance of combination therapies are expected to further propel market growth. As the focus on personalized healthcare intensifies, the therapeutic vaccines market is poised for substantial expansion.

Restraints and Challenges:

The therapeutic vaccines market is confronted with several notable restraints and challenges. A primary challenge is the high cost of vaccine development, which necessitates substantial investment in research and clinical trials. This financial burden can deter smaller companies and limit innovation. Regulatory hurdles also present significant obstacles; navigating complex approval processes can delay market entry and increase costs. Additionally, the market faces issues with public perception and vaccine hesitancy, which can impede acceptance and uptake. The logistical challenges of distribution, especially in low-resource settings, further complicate market expansion. Ensuring cold chain integrity and reaching remote areas are persistent difficulties. Lastly, the variability in disease prevalence across regions necessitates tailored vaccine solutions, complicating standardization and scalability. These factors collectively pose significant challenges to the growth and accessibility of therapeutic vaccines.

Key Players:

Inovio Pharmaceuticals, Bavarian Nordic, Hookipa Pharma, GlobeImmune, ImmunoVaccine Technologies, Valneva, OncoTherapy Science, Vaxil BioTherapeutics, CEL-SCI Corporation, Transgene, Agenus, Scancell Holdings, Oncolytics Biotech, Genocea Biosciences, Heat Biologics, BioNTech, Altimmune, VBI Vaccines, Imugene, Vaccibody

Research Scope:

  • Estimates and forecasts the overall market size across type, application, and region.
  • Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
  • Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
  • Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
  • Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
  • Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
  • Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1 Executive Summary

  • 1.1 Market Size and Forecast
  • 1.2 Market Overview
  • 1.3 Market Snapshot
  • 1.4 Regional Snapshot
  • 1.5 Strategic Recommendations
  • 1.6 Analyst Notes

2 Market Highlights

  • 2.1 Key Market Highlights by Type
  • 2.2 Key Market Highlights by Product
  • 2.3 Key Market Highlights by Technology
  • 2.4 Key Market Highlights by Application
  • 2.5 Key Market Highlights by End User
  • 2.6 Key Market Highlights by Component
  • 2.7 Key Market Highlights by Process
  • 2.8 Key Market Highlights by Deployment
  • 2.9 Key Market Highlights by Solutions

3 Market Dynamics

  • 3.1 Macroeconomic Analysis
  • 3.2 Market Trends
  • 3.3 Market Drivers
  • 3.4 Market Opportunities
  • 3.5 Market Restraints
  • 3.6 CAGR Growth Analysis
  • 3.7 Impact Analysis
  • 3.8 Emerging Markets
  • 3.9 Technology Roadmap
  • 3.10 Strategic Frameworks
    • 3.10.1 PORTER's 5 Forces Model
    • 3.10.2 ANSOFF Matrix
    • 3.10.3 4P's Model
    • 3.10.4 PESTEL Analysis

4 Segment Analysis

  • 4.1 Market Size & Forecast by Type (2020-2035)
    • 4.1.1 Cancer Vaccines
    • 4.1.2 Infectious Disease Vaccines
    • 4.1.3 Autoimmune Disease Vaccines
    • 4.1.4 Neurological Disorder Vaccines
  • 4.2 Market Size & Forecast by Product (2020-2035)
    • 4.2.1 Prophylactic Vaccines
    • 4.2.2 Therapeutic Vaccines
  • 4.3 Market Size & Forecast by Technology (2020-2035)
    • 4.3.1 Recombinant Technology
    • 4.3.2 Conjugate Vaccines
    • 4.3.3 Live Attenuated Vaccines
    • 4.3.4 Inactivated Vaccines
    • 4.3.5 Synthetic Vaccines
  • 4.4 Market Size & Forecast by Application (2020-2035)
    • 4.4.1 Oncology
    • 4.4.2 Infectious Diseases
    • 4.4.3 Autoimmune Disorders
    • 4.4.4 Neurological Disorders
  • 4.5 Market Size & Forecast by End User (2020-2035)
    • 4.5.1 Hospitals
    • 4.5.2 Clinics
    • 4.5.3 Research Institutes
    • 4.5.4 Pharmaceutical Companies
  • 4.6 Market Size & Forecast by Component (2020-2035)
    • 4.6.1 Antigens
    • 4.6.2 Adjuvants
  • 4.7 Market Size & Forecast by Process (2020-2035)
    • 4.7.1 Preclinical Testing
    • 4.7.2 Clinical Trials
    • 4.7.3 Manufacturing
  • 4.8 Market Size & Forecast by Deployment (2020-2035)
    • 4.8.1 On-premise
    • 4.8.2 Cloud-based
  • 4.9 Market Size & Forecast by Solutions (2020-2035)
    • 4.9.1 Vaccine Development
    • 4.9.2 Vaccine Manufacturing
    • 4.9.3 Vaccine Distribution

5 Regional Analysis

  • 5.1 Global Market Overview
  • 5.2 North America Market Size (2020-2035)
    • 5.2.1 United States
      • 5.2.1.1 Type
      • 5.2.1.2 Product
      • 5.2.1.3 Technology
      • 5.2.1.4 Application
      • 5.2.1.5 End User
      • 5.2.1.6 Component
      • 5.2.1.7 Process
      • 5.2.1.8 Deployment
      • 5.2.1.9 Solutions
    • 5.2.2 Canada
      • 5.2.2.1 Type
      • 5.2.2.2 Product
      • 5.2.2.3 Technology
      • 5.2.2.4 Application
      • 5.2.2.5 End User
      • 5.2.2.6 Component
      • 5.2.2.7 Process
      • 5.2.2.8 Deployment
      • 5.2.2.9 Solutions
    • 5.2.3 Mexico
      • 5.2.3.1 Type
      • 5.2.3.2 Product
      • 5.2.3.3 Technology
      • 5.2.3.4 Application
      • 5.2.3.5 End User
      • 5.2.3.6 Component
      • 5.2.3.7 Process
      • 5.2.3.8 Deployment
      • 5.2.3.9 Solutions
  • 5.3 Latin America Market Size (2020-2035)
    • 5.3.1 Brazil
      • 5.3.1.1 Type
      • 5.3.1.2 Product
      • 5.3.1.3 Technology
      • 5.3.1.4 Application
      • 5.3.1.5 End User
      • 5.3.1.6 Component
      • 5.3.1.7 Process
      • 5.3.1.8 Deployment
      • 5.3.1.9 Solutions
    • 5.3.2 Argentina
      • 5.3.2.1 Type
      • 5.3.2.2 Product
      • 5.3.2.3 Technology
      • 5.3.2.4 Application
      • 5.3.2.5 End User
      • 5.3.2.6 Component
      • 5.3.2.7 Process
      • 5.3.2.8 Deployment
      • 5.3.2.9 Solutions
    • 5.3.3 Rest of Latin America
      • 5.3.3.1 Type
      • 5.3.3.2 Product
      • 5.3.3.3 Technology
      • 5.3.3.4 Application
      • 5.3.3.5 End User
      • 5.3.3.6 Component
      • 5.3.3.7 Process
      • 5.3.3.8 Deployment
      • 5.3.3.9 Solutions
  • 5.4 Asia-Pacific Market Size (2020-2035)
    • 5.4.1 China
      • 5.4.1.1 Type
      • 5.4.1.2 Product
      • 5.4.1.3 Technology
      • 5.4.1.4 Application
      • 5.4.1.5 End User
      • 5.4.1.6 Component
      • 5.4.1.7 Process
      • 5.4.1.8 Deployment
      • 5.4.1.9 Solutions
    • 5.4.2 India
      • 5.4.2.1 Type
      • 5.4.2.2 Product
      • 5.4.2.3 Technology
      • 5.4.2.4 Application
      • 5.4.2.5 End User
      • 5.4.2.6 Component
      • 5.4.2.7 Process
      • 5.4.2.8 Deployment
      • 5.4.2.9 Solutions
    • 5.4.3 South Korea
      • 5.4.3.1 Type
      • 5.4.3.2 Product
      • 5.4.3.3 Technology
      • 5.4.3.4 Application
      • 5.4.3.5 End User
      • 5.4.3.6 Component
      • 5.4.3.7 Process
      • 5.4.3.8 Deployment
      • 5.4.3.9 Solutions
    • 5.4.4 Japan
      • 5.4.4.1 Type
      • 5.4.4.2 Product
      • 5.4.4.3 Technology
      • 5.4.4.4 Application
      • 5.4.4.5 End User
      • 5.4.4.6 Component
      • 5.4.4.7 Process
      • 5.4.4.8 Deployment
      • 5.4.4.9 Solutions
    • 5.4.5 Australia
      • 5.4.5.1 Type
      • 5.4.5.2 Product
      • 5.4.5.3 Technology
      • 5.4.5.4 Application
      • 5.4.5.5 End User
      • 5.4.5.6 Component
      • 5.4.5.7 Process
      • 5.4.5.8 Deployment
      • 5.4.5.9 Solutions
    • 5.4.6 Taiwan
      • 5.4.6.1 Type
      • 5.4.6.2 Product
      • 5.4.6.3 Technology
      • 5.4.6.4 Application
      • 5.4.6.5 End User
      • 5.4.6.6 Component
      • 5.4.6.7 Process
      • 5.4.6.8 Deployment
      • 5.4.6.9 Solutions
    • 5.4.7 Rest of APAC
      • 5.4.7.1 Type
      • 5.4.7.2 Product
      • 5.4.7.3 Technology
      • 5.4.7.4 Application
      • 5.4.7.5 End User
      • 5.4.7.6 Component
      • 5.4.7.7 Process
      • 5.4.7.8 Deployment
      • 5.4.7.9 Solutions
  • 5.5 Europe Market Size (2020-2035)
    • 5.5.1 Germany
      • 5.5.1.1 Type
      • 5.5.1.2 Product
      • 5.5.1.3 Technology
      • 5.5.1.4 Application
      • 5.5.1.5 End User
      • 5.5.1.6 Component
      • 5.5.1.7 Process
      • 5.5.1.8 Deployment
      • 5.5.1.9 Solutions
    • 5.5.2 France
      • 5.5.2.1 Type
      • 5.5.2.2 Product
      • 5.5.2.3 Technology
      • 5.5.2.4 Application
      • 5.5.2.5 End User
      • 5.5.2.6 Component
      • 5.5.2.7 Process
      • 5.5.2.8 Deployment
      • 5.5.2.9 Solutions
    • 5.5.3 United Kingdom
      • 5.5.3.1 Type
      • 5.5.3.2 Product
      • 5.5.3.3 Technology
      • 5.5.3.4 Application
      • 5.5.3.5 End User
      • 5.5.3.6 Component
      • 5.5.3.7 Process
      • 5.5.3.8 Deployment
      • 5.5.3.9 Solutions
    • 5.5.4 Spain
      • 5.5.4.1 Type
      • 5.5.4.2 Product
      • 5.5.4.3 Technology
      • 5.5.4.4 Application
      • 5.5.4.5 End User
      • 5.5.4.6 Component
      • 5.5.4.7 Process
      • 5.5.4.8 Deployment
      • 5.5.4.9 Solutions
    • 5.5.5 Italy
      • 5.5.5.1 Type
      • 5.5.5.2 Product
      • 5.5.5.3 Technology
      • 5.5.5.4 Application
      • 5.5.5.5 End User
      • 5.5.5.6 Component
      • 5.5.5.7 Process
      • 5.5.5.8 Deployment
      • 5.5.5.9 Solutions
    • 5.5.6 Rest of Europe
      • 5.5.6.1 Type
      • 5.5.6.2 Product
      • 5.5.6.3 Technology
      • 5.5.6.4 Application
      • 5.5.6.5 End User
      • 5.5.6.6 Component
      • 5.5.6.7 Process
      • 5.5.6.8 Deployment
      • 5.5.6.9 Solutions
  • 5.6 Middle East & Africa Market Size (2020-2035)
    • 5.6.1 Saudi Arabia
      • 5.6.1.1 Type
      • 5.6.1.2 Product
      • 5.6.1.3 Technology
      • 5.6.1.4 Application
      • 5.6.1.5 End User
      • 5.6.1.6 Component
      • 5.6.1.7 Process
      • 5.6.1.8 Deployment
      • 5.6.1.9 Solutions
    • 5.6.2 United Arab Emirates
      • 5.6.2.1 Type
      • 5.6.2.2 Product
      • 5.6.2.3 Technology
      • 5.6.2.4 Application
      • 5.6.2.5 End User
      • 5.6.2.6 Component
      • 5.6.2.7 Process
      • 5.6.2.8 Deployment
      • 5.6.2.9 Solutions
    • 5.6.3 South Africa
      • 5.6.3.1 Type
      • 5.6.3.2 Product
      • 5.6.3.3 Technology
      • 5.6.3.4 Application
      • 5.6.3.5 End User
      • 5.6.3.6 Component
      • 5.6.3.7 Process
      • 5.6.3.8 Deployment
      • 5.6.3.9 Solutions
    • 5.6.4 Sub-Saharan Africa
      • 5.6.4.1 Type
      • 5.6.4.2 Product
      • 5.6.4.3 Technology
      • 5.6.4.4 Application
      • 5.6.4.5 End User
      • 5.6.4.6 Component
      • 5.6.4.7 Process
      • 5.6.4.8 Deployment
      • 5.6.4.9 Solutions
    • 5.6.5 Rest of MEA
      • 5.6.5.1 Type
      • 5.6.5.2 Product
      • 5.6.5.3 Technology
      • 5.6.5.4 Application
      • 5.6.5.5 End User
      • 5.6.5.6 Component
      • 5.6.5.7 Process
      • 5.6.5.8 Deployment
      • 5.6.5.9 Solutions

6 Market Strategy

  • 6.1 Demand-Supply Gap Analysis
  • 6.2 Trade & Logistics Constraints
  • 6.3 Price-Cost-Margin Trends
  • 6.4 Market Penetration
  • 6.5 Consumer Analysis
  • 6.6 Regulatory Snapshot

7 Competitive Intelligence

  • 7.1 Market Positioning
  • 7.2 Market Share
  • 7.3 Competition Benchmarking
  • 7.4 Top Company Strategies

8 Company Profiles

  • 8.1 Inovio Pharmaceuticals
    • 8.1.1 Overview
    • 8.1.2 Product Summary
    • 8.1.3 Financial Performance
    • 8.1.4 SWOT Analysis
  • 8.2 Bavarian Nordic
    • 8.2.1 Overview
    • 8.2.2 Product Summary
    • 8.2.3 Financial Performance
    • 8.2.4 SWOT Analysis
  • 8.3 Hookipa Pharma
    • 8.3.1 Overview
    • 8.3.2 Product Summary
    • 8.3.3 Financial Performance
    • 8.3.4 SWOT Analysis
  • 8.4 GlobeImmune
    • 8.4.1 Overview
    • 8.4.2 Product Summary
    • 8.4.3 Financial Performance
    • 8.4.4 SWOT Analysis
  • 8.5 ImmunoVaccine Technologies
    • 8.5.1 Overview
    • 8.5.2 Product Summary
    • 8.5.3 Financial Performance
    • 8.5.4 SWOT Analysis
  • 8.6 Valneva
    • 8.6.1 Overview
    • 8.6.2 Product Summary
    • 8.6.3 Financial Performance
    • 8.6.4 SWOT Analysis
  • 8.7 OncoTherapy Science
    • 8.7.1 Overview
    • 8.7.2 Product Summary
    • 8.7.3 Financial Performance
    • 8.7.4 SWOT Analysis
  • 8.8 Vaxil BioTherapeutics
    • 8.8.1 Overview
    • 8.8.2 Product Summary
    • 8.8.3 Financial Performance
    • 8.8.4 SWOT Analysis
  • 8.9 CEL-SCI Corporation
    • 8.9.1 Overview
    • 8.9.2 Product Summary
    • 8.9.3 Financial Performance
    • 8.9.4 SWOT Analysis
  • 8.10 Transgene
    • 8.10.1 Overview
    • 8.10.2 Product Summary
    • 8.10.3 Financial Performance
    • 8.10.4 SWOT Analysis
  • 8.11 Agenus
    • 8.11.1 Overview
    • 8.11.2 Product Summary
    • 8.11.3 Financial Performance
    • 8.11.4 SWOT Analysis
  • 8.12 Scancell Holdings
    • 8.12.1 Overview
    • 8.12.2 Product Summary
    • 8.12.3 Financial Performance
    • 8.12.4 SWOT Analysis
  • 8.13 Oncolytics Biotech
    • 8.13.1 Overview
    • 8.13.2 Product Summary
    • 8.13.3 Financial Performance
    • 8.13.4 SWOT Analysis
  • 8.14 Genocea Biosciences
    • 8.14.1 Overview
    • 8.14.2 Product Summary
    • 8.14.3 Financial Performance
    • 8.14.4 SWOT Analysis
  • 8.15 Heat Biologics
    • 8.15.1 Overview
    • 8.15.2 Product Summary
    • 8.15.3 Financial Performance
    • 8.15.4 SWOT Analysis
  • 8.16 BioNTech
    • 8.16.1 Overview
    • 8.16.2 Product Summary
    • 8.16.3 Financial Performance
    • 8.16.4 SWOT Analysis
  • 8.17 Altimmune
    • 8.17.1 Overview
    • 8.17.2 Product Summary
    • 8.17.3 Financial Performance
    • 8.17.4 SWOT Analysis
  • 8.18 VBI Vaccines
    • 8.18.1 Overview
    • 8.18.2 Product Summary
    • 8.18.3 Financial Performance
    • 8.18.4 SWOT Analysis
  • 8.19 Imugene
    • 8.19.1 Overview
    • 8.19.2 Product Summary
    • 8.19.3 Financial Performance
    • 8.19.4 SWOT Analysis
  • 8.20 Vaccibody
    • 8.20.1 Overview
    • 8.20.2 Product Summary
    • 8.20.3 Financial Performance
    • 8.20.4 SWOT Analysis

9 About Us

  • 9.1 About Us
  • 9.2 Research Methodology
  • 9.3 Research Workflow
  • 9.4 Consulting Services
  • 9.5 Our Clients
  • 9.6 Client Testimonials
  • 9.7 Contact Us